Specification Setting: Setting Acceptance Criteria from Statistics of the Data - - BioPharm International


Specification Setting: Setting Acceptance Criteria from Statistics of the Data

BioPharm International
Volume 19, Issue 11

If we do not know μ and σ, we must use early production test results to determine if the distribution can be regarded as Normal and to estimate the mean and standard deviation. As was pointed out earlier, estimates of μ and σ calculated from samples are subject to uncertainty due to sampling variability. This uncertainty requires us to adopt a probabilistic approach to the tolerance limits such that we make statements like the following: "We are 99% confident that 99% of the measurements will fall within the calculated tolerance limits." The uncertainty, or lack of confidence, is reflected in sigma multipliers that are larger than would be the case if we knew μ and σ. The increase depends on the sample size. The comments attributed to Shewhart suggest that the effect of sample variability will be close to zero for samples larger than 250.

Methods of calculating probabilistic tolerance limits can be found in the National Institute of Standards of Technology (NIST)/SEMATECH e-Handbook of Statistical Methods.3

The method for a two-sided tolerance interval can be found in a 1969 paper attributed to Howe.4 This author calculates a variable MUL to provide us with a level of confidence of C% that the limits (x mean – MUL * s) and (x mean + MUL * s) will contain D% of the distribution.

The method for calculating probabilistic one-sided tolerance intervals that is set out in the NIST/SEMATECH e-Handbook of Statistical Methods is attributed to Natrella.5 The upper limit providing a level of confidence of C% that D% of the values will be less than it is given by (x mean + MU * s). The lower limit is defined similarly as (x mean – ML * s).

Table 1. Two-sided multipliers (MUL) and one-sided multipliers (MU or ML) for sample sizes up to N = 200
Since the effect of sample variability will be close to zero for samples larger than 250, when constructing Table 1, the aim was to produce values of the sigma multipliers (MUL, ML, and MU) that are around 3.0 when the sample size is 250. Thus C% was set to 99% and D% was set to 99.25%.

We can use the residual 1,3–diacetyl benzene results shown in Figure 1 as an example. Typically, there is an upper specification limit for such residual compounds. The statistical software Minitab was used to test for Normality and to calculate estimates of the mean and standard deviation.

The Anderson-Darling A-squared statistic was 0.24 and the P-value was 0.75. A P-value larger than 0.05 indicates that the distribution is not significantly different than Normal. Thus, we can regard the distribution of the residual 1,3–diacetyl benzene results as Normal.

The one-sided tolerance interval procedure was used because only an upper limit is needed. Table 1 shows the value of MU for a sample size of 62 to be 3.46. The calculation set out below resulted in an upper limit of 460 μg/g:
Mean = 245.7 μg/g
Standard deviation = 61.91 μg/g
Sample size = 62
Sigma multiplier = 3.46
Upper specification limit = 460 μg/g

What can be done when the distribution looks Normal but fails a test?

A similar upper specification limit was required for 1,4-diacetyl benzene, but this time the Anderson-Darling test indicated that that the distribution of the sample was significantly different from a Normal.

blog comments powered by Disqus



Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here